Why Moderna Stock Slumped on Tuesday
Tuesday wasn't one of the better days to be a Moderna (NASDAQ: MRNA) shareholder. The high-profile biotech's stock price dropped by almost 3%, on the back of a general pullback in coronavirus stocks. A fresh whistleblower complaint from a major charity didn't help either.
The broader stock market generally did well on Tuesday, with the S&P 500 index gaining nearly 2%. Investors were veering away from vaccine stocks, though, as more evidence is piling up that omicron might not be as threatening as feared. Yes, the variant is spreading fast, but it seems to cause a notably milder form of COVID-19.
Image source: Getty Images.
Source Fool.com
